INTRODUCTION AND OBJECTIVES:
Percutaneous thermal ablation is a minimally invasive nephron-sparing treatment for RCC that provides an alternative to surgery for co-morbid patients. Most cryotherapy and RFA studies have focused on treatment of small RCC but treatment of larger tumors may be facilitated with high power microwave ablation (MWA). The purpose of this study is to compare oncologic outcomes for RCC patients with clinical T1b tumors following surgery or MWA.
METHODS: Comprehensive data was collected for consecutive RCC patients with cT1b tumors following treatment with MWA (NeuWave Medical), partial nephrectomy (PN) or radical nephrectomy (RN). Locally advanced or metastatic tumors were excluded. Patients were offered MWA after failing (growth >5mm/year) or refusing active surveillance. Univariate and multivariate Cox analysis evaluated associations between variables and survival outcomes.
RESULTS: A total of 326 patients (41 MWA, 74 PN and 211 RN) were identified between 2000-2017. Patients treated with MWA were older (p<0.001) and more comorbid (p<0.001) vs. surgery patients. No difference identified in gender, race, BMI, eGFR, and tumor diameter. Median follow-up was 41 months (IQR 14-81 months).
Local recurrence was identified in 3, 1, and 1 patients following MWA, PN, and RN. 5-year local recurrence free survival was lower following MWA (91.2%) vs. PN (97.9%) or RN (99.2%); p[0.001).
Three patients with local recurrence following MWA were treated with repeat ablation and had no evidence of residual disease after median of 29 months from the second ablation.
Progression Percutaneous cryoablation(PCA) is mentioned as only option for cT1 renal tumor because recurrence rate is relatively higher than that in partial nephrectomy. Salvage cryoablation can be performed for recurrent tumor, however its utility is unclear. We evaluated the utility and safety in patients treated with salvage cryoablation for recurrent tumor after primary PCA for cT1 renal tumor.
METHODS: We retrospectively analyzed the record of the patients who underwent PCA in our institution between November 2011 and March 2018. First, we analyzed overall survival(OS), cancer specific survival(CSS) and local recurrence free survival(L-RFS) in primary PCA using the Kaplan-Meier method and compared with log-rank tests. Second, we analyzed perioperative outcome and renal function and oncological outcome of salvage PCA compared with primary PCA.
RESULTS: A total 189 tumors underwent PCA (Primary: n [171, Salvage: n[18) . In Primary PCA group, 13 (7.6%) residues and 10 (5.8%) recurrences were later diagnosed. The median follow-up period was 26 months. The 3-year OS and CSS were 97.3% (95% CI:91.5-99.2) and 99.4% (95%CI:95.5-99.9) respectively. The 3-year L-RFS was 85.7% (95%CI:78.0-90.9). In multivariate analysis by cox proportional hazard model, age and high R.E.N.A.L score (>10) were independent prognostic factor for recurrence. In comparing Primary with Salvage PCA, perioperative overall complication rate had no significant difference in both groups. The 3-year L-RFS was no significant difference, Primary: 85.7% (78.0-90.9) vs. Salvage: 80.8% (41.0-95.0, P[0.854). Two patients in Salvage group had recurrence at 6 and 23 months respectively and underwent a third salvage PCA successfully. All tumors in Salvage group were able to be locally controlled.
CONCLUSIONS: Although PCA has higher local recurrence rate, local control can be obtained by salvage PCA. Salvage PCA after primary cryoablation failure is feasible, has a low complication rate, and acceptable mid-term oncologic outcomes. Further studies with durable follow-up are required.
Renal cell carcinoma (RCC) has several histologic subtypes, which have shown potential for differential clinical outcomes. Our study objective was to evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN).
METHODS: We queried the National Cancer Data Base (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) for patients with T1a RCC who were treated surgically. OS was estimated by Kaplan-Meier curves based on histologic subtype and management. Cox proportional regression models were used to determine whether histologic subtypes and management procedure predicted OS. Our adjusted model included age, sex, race/ethnicity, insurance status, median income, proportion without high school diploma, urbanicity, Charlson-Deyo index, tumor grade, and facility volume.
RESULTS: Of the 52,245 T1a masses that met inclusion criteria, 51.1% were clear cell, followed by papillary (34.8%), chromophobe (11.8%), cystic (1.8%), sarcomatoid (0.4%) and collecting duct (0.2%). PN was performed in 51%, RN in 31%, and 18% had PA. Kaplan Meier curves demonstrated differences in survival by histology among clear cell, papillary, chromophobe, and cystic subtypes (all p<0.001), but not for sarcomatoid (p[0.110) 43-2.58] ). Predictive models using cox proportional hazards incorporating histology and surgical procedure alone were limited (c-index 0.63) while adding demographics demonstrated fair predictive power for OS (c-index 0.73) (Figure 1b) .
CONCLUSIONS: In patients with T1a RCC, OS differs by histologic subtype. PN appears to be superior to both PA and RN. Incorporating histologic subtype and treatment modality into a risk stratification model to predict OS appears to have limited utility compared with variables representing competing risks. Given the preponderance of T1a RCC, more systematic methods of weighing competing risks are needed for deciding upon optimal management. There is a fundamental lack of knowledge regarding patients with muscle-invasive bladder cancer (MIBC) that are left untreated.This is an important point when counseling patients. In an effort to address this void, we leveraged the Stockholm cohort for patients with MIBC who did not receive any additional treatment after TURBT, and compared their outcomes with patients who received treatment with curative intent.
METHODS: All patients diagnosed with bladder cancer during 1995-1996 in the Stockholm county were collected in a population based cohort consisting of 735 patients. 126 patients diagnosed with non-metastatic MIBC were identified. Kaplan-Meier and cumulative incidence curves were used to evaluate overall survival (OS) and cancer specific mortality (CSM). A multivariable Cox regression was fitted to predict OS; whereas a competing risks regression was adopted for the prediction of CSM, after accounting for other cause mortality (OCM). Analyses were adjusted for age at diagnosis, sex, clinical stage, tumor stage and treatment (yes vs. no).
RESULTS: Overall, 64 (51%) patients did not receive any treatment because of advanced age or comorbidity, whereas 62 (49%) received treatment with curative intent, as either radical cystectomy: 47 or radiation therapy: 15. For untreated patients, median (IQR) age at diagnosis was 79 (63-83) yrs vs. 69 (63-74) in the treated group (p<0.001). The median follow-up for survivors was 14.4 yrs; 109 patients died during follow-up, 89 of them experienced CSM. The 5-yr OS rate for untreated patients was 5% (95%CI: 1-12%) vs. 48% (95% CI: 36-60%) of treated patients. Patients not receiving any treatment had a 5-yr cumulative incidence of CSM of 86% (95%CI: 75-94%) vs.
